Wellbeing Whisper on MSN
Eli Lilly lowers Zepbound vial prices amid intensifying GLP-1 competition
The steep monthly costs of GLP-1 medications have long been a major obstacle for many patients trying to find effective ...
Smithsonian Magazine on MSN
Here’s What the World Health Organization Had to Say About GLP-1s in its First-Ever Guideline on the Drugs
The health agency supports the long-term use of the medications in combination with a healthy diet and exercise, and calls ...
A well-planned public health agenda that incorporates GLP-1 drugs has the potential to reduce obesity rates, increase life expectancy, and narrow the mortality gap between the U.S. and other ...
While the WHO study saw reports of suicidal thoughts were slightly higher for semaglutide in particular, the warning applies ...
Everyday Health on MSN
New Obesity Drug Helped People Lose Nearly One-Third Their Body Weight
The clinical trial showed this experimental medication to be much more effective than any existing GLP-1 drug. But that much ...
MedPage Today on MSN
New Guidelines on GLP-1 Drugs for Obesity Released
The recommended use of GLP-1 therapies, including tirzepatide (Zepbound), semaglutide (Wegovy), and liraglutide (Saxenda), ...
Eli Lilly's new obesity drug shows promising results in weight loss, surpassing its existing drug Zepbound, as competition in ...
GLP-1 medications have become game changers for people trying to lose weight, but bariatric surgery is still superior when it comes to total and lasting weight loss, a new study has found. Patients ...
Some patients dropped out of the trial early because they had lost so much weight.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback